

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “EGM”) of 深圳市海王英特龍生物技術股份有限公司 (Shenzhen Neptunus Interlong Bio-technique Company Limited*) (the “**Company**”, together with its subsidiaries, the “**Group**”) will be held at 10:00 a.m., on Friday, 14 January 2022 at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, the People's Republic of China (the “**PRC**”), for the purpose of considering and, if thought fit, passing, with or without modifications, the following resolution.

ORDINARY RESOLUTION

1. “**THAT**

- (a) the form and substance of the healthcare food and food purchase framework agreement (the “**2021 Healthcare Food and Food Purchase Framework Agreement**”) dated 6 December 2021 entered into between the Company and 深圳海王集團股份有限公司 (Shenzhen Neptunus Group Company Limited*) (“**Neptunus Group**”) relating to the purchase of certain food and healthcare food products by the Company from Neptunus Group and its subsidiaries (excluding the Group) or any one of them, for them to distribute within the PRC (a copy of the 2021 Healthcare Food and Food Purchase Framework Agreement has been produced to the meeting and marked “A” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;
- (b) the form and substance of the distribution agreement (the “**2021 Distribution Agreement**”) dated 6 December 2021 entered into between 深圳海王長健醫藥有限公司 (Shenzhen Neptunus Changjian Pharmaceutical Company Limited*) (“**Neptunus Changjian**”), a wholly-owned subsidiary of the Company, and 深圳海王藥業有限公司 (Shenzhen Neptunus Pharmaceutical Company Limited*) (“**Neptunus Pharmaceutical**”), a wholly-owned subsidiary of Neptunus Group, relating to the purchase of pharmaceutical products by Neptunus Changjian from Neptunus Pharmaceutical for them to distribute in the PRC (a copy of the 2021 Distribution Agreement has been produced to the meeting and marked “B” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;

- (c) the proposed purchase caps under the 2021 Healthcare Food and Food Purchase Framework Agreement for each of the years ending 31 December 2022, 2023 and 2024 be and are hereby confirmed and approved;
- (d) the proposed purchase caps under the 2021 Distribution Agreement for each of the years ending 31 December 2022, 2023 and 2024 be and are hereby confirmed and approved; and
- (e) any one director of the Company (the “**Director**”) be and is hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Directors may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2021 Healthcare Food and Food Purchase Framework Agreement, the 2021 Distribution Agreement, or any transactions contemplated thereunder.”

Please refer to the Company’s announcement dated 6 December 2021 for details of the 2021 Healthcare Food and Food Purchase Framework Agreement and details of the 2021 Distribution Agreement. In accordance with the requirements under Rule 20.44(1) and Rule 25.34A of the Rules Governing the Listing of Securities on GEM of the Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the PRC Company Law, the Company will deliver a circular containing details of the 2021 Healthcare Food and Food Purchase Framework Agreement and details of the 2021 Distribution Agreement and the transactions contemplated thereunder to the Shareholders as soon as possible.

By order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, PRC, 17 December 2021

Registered office:
Suite 2103, 21st Floor,
Neptunus Yinhe Technology Mansion,
1 Keji Middle 3rd Road,
Yuehai Sub-district,
Nanshan District,
Shenzhen,
Guangdong Province,
PRC

Principal place of business in Hong Kong:
18th Floor, United Centre,
95 Queensway,
Admiralty,
Hong Kong

* *For identification purpose only*

Notes:

1. A shareholder of the Company (the “**Shareholder**”) entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote instead of him. A proxy need not be a Shareholder. In the case of joint holders of shares of the Company (the “**Shares**”), any one of such joint holders may sign the form of proxy. However, if more than one of such joint holders are present at the EGM, whether personally or by proxy, that one of the joint Shareholders so present whose name stands first in the register of Shareholders in respect of such Shares shall alone be entitled to vote in respect thereof.
2. In order to be valid, the form of proxy together with a power of attorney or other authority (if any) under which it is signed or the notarised copy of such power of attorney or authority must be lodged not less than 24 hours before the day appointed for the EGM (i.e. not later than 10:00 a.m. on Thursday, 13 January 2022), in the case of holders of H shares of the Company (the “**H Shares**”), with the Company’s H share registrar and transfer office in Hong Kong, Tricor Investor Services Limited (the “**Company’s H Share Registrar and Transfer Office**”) at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong, and in the case of holders of domestic shares of the Company (the “**Domestic Shares**”), to the Company’s registered office at Suite 2103, 21st Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Yuehai Sub-district, Nanshan District, Shenzhen, Guangdong Province, the PRC.
3. The Shareholders or their proxies will be required to produce proof of their identities (and a copy of the form of proxy in case of proxies) when attending the EGM.
4. To ascertain the Shareholders’ entitlement to attend and vote at the EGM, the register of Shareholders will be closed from Tuesday, 11 January 2022 to Friday, 14 January 2022, both days inclusive, during which no transfer of Shares will be effected. As regards holders of H Shares, in order to qualify for attending the EGM, all transfers of H Shares accompanied by the relevant share certificates must be lodged with the Company’s H Share Registrar and Transfer Office, at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong not later than 4:30 p.m. on Monday, 10 January 2022.
5. The EGM is expected to last for no more than a day. The Shareholders or their proxies attending the EGM shall bear their own traveling, accommodation and meal expenses.
6. Voting at the EGM will be conducted by way of poll.
7. For any enquiries about this notice, please contact the contact person of the general meetings, Mr. Huang Jian Bo, at +86 755 2640 1275.
8. References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this notice, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Xu Yan He; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This notice, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this notice is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this notice misleading.

This notice will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.